Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1972 1
1975 1
1977 2
1979 1
1980 1
1982 1
1984 2
1985 1
1989 2
1992 4
1993 1
1994 2
1995 9
1996 6
1997 6
1998 1
1999 3
2000 4
2001 2
2002 7
2003 2
2004 3
2005 5
2006 6
2007 10
2008 6
2009 4
2010 10
2011 12
2012 12
2013 9
2014 16
2015 16
2016 14
2017 14
2018 17
2019 21
2020 23
2021 27
2022 33
2023 26
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. FUNDING: Travere Therapeutics....
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term …
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The efficacy and safety of longer-term treatment with sparsentan for FSGS are unknown. METHODS: In this phase 3 trial, we enrolled patient …
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The e …
NAD+ regulates nucleotide metabolism and genomic DNA replication.
Munk SHN, Merchut-Maya JM, Adelantado Rubio A, Hall A, Pappas G, Milletti G, Lee M, Johnsen LG, Guldberg P, Bartek J, Maya-Mendoza A. Munk SHN, et al. Among authors: hall a. Nat Cell Biol. 2023 Dec;25(12):1774-1786. doi: 10.1038/s41556-023-01280-z. Epub 2023 Nov 13. Nat Cell Biol. 2023. PMID: 37957325 Free PMC article.
Here we show that exogenous NAD(+), but not its precursors, has a direct effect on mitochondrial activity. Short-term incubation with NAD(+) boosts Kreb's cycle and the electron transport chain and enhances pyrimidine biosynthesis. ...
Here we show that exogenous NAD(+), but not its precursors, has a direct effect on mitochondrial activity. Short-term incubation with …
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
Tomás CC, Oliveira E, Sousa D, Uba-Chupel M, Furtado G, Rocha C, Teixeira A, Ferreira P, Alves C, Gisin S, Catarino E, Carvalho N, Coucelo T, Bonfim L, Silva C, Franco D, González JA, Jardim HG, Silva R, Baixinho CL, Presado MªH, Marques MªF, Cardoso ME, Cunha M, Mendes J, Xavier A, Galhardo A, Couto M, Frade JG, Nunes C, Mesquita JR, Nascimento MS, Gonçalves G, Castro C, Mártires A, Monteiro MªJ, Rainho C, Caballero FP, Monago FM, Guerrero JT, Monago RM, Trigo AP, Gutierrez ML, Milanés GM, Reina MG, Villanueva AG, Piñero AS, Aliseda IR, Ramirez FB, Ribeiro A, Quelhas A, Manso C, Caballero FP, Guerrero JT, Monago FM, Santos RB, Jimenez NR, Nuñez CG, Gomez IR, Fernandez MªJL, Marquez LA, Moreno AL, Huertas MªJT, Ramirez FB, Seabra D, Salvador MªC, Braga L, Parreira P, Salgueiro-Oliveira A, Arreguy-Sena C, Oliveira BF, Henriques MªA, Santos J, Lebre S, Marques A, Festas C, Rodrigues S, Ribeiro A, Lumini J, Figueiredo AG, Hernandez-Martinez FJ, Campi L, Quintana-Montesdeoca MªP, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Parente A, Mata MªA, Pereira AMª, Fernandes A, Brás M, Pinto MªR, Parreira P, Basto ML, Rei AC, Mónico LM, Sousa G, Morna C, Freitas O, Freitas G, Jardim A, Vasconcelos … See abstract for full author list ➔ Tomás CC, et al. Among authors: hall a. BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5. BMC Health Serv Res. 2016. PMID: 27409075 Free PMC article.
Silva, Rafaela Rosario P40 Coping strategies of college students Luis Pimenta, Diana Carreira, Patricia Teles, Teresa Barros P41 Emotional intelligence and mental health stigma in health students Catarina Tomas, Ana Querido, Daniel Carvalho, Joao Gomes, Marina Cordeiro P42 Stigma …
Silva, Rafaela Rosario P40 Coping strategies of college students Luis Pimenta, Diana Carreira, Patricia Teles, Teresa Barros P41 Emotional i …
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, Al-Beidh F, Annane D, Arabi YM, Beane A, van Bentum-Puijk W, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Charles WN, Cove M, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Horvat CM, Huang DT, Ichihara N, Lamontagne F, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Neal MD, Nichol AD, Parke RL, Parker JC, Parry-Billings K, Peters SEC, Reyes LF, Rowan KM, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Stronach LM, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Gordon AC, Webb SA, Lawler PR. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257. JAMA. 2023. PMID: 36525245 Free PMC article.
IMPORTANCE: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. OBJECTIVE: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. DESIGN, SETTING, AN …
IMPORTANCE: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. OBJECTIVE: T …
Drug compound screening in single and integrated multi-organoid body-on-a-chip systems.
Skardal A, Aleman J, Forsythe S, Rajan S, Murphy S, Devarasetty M, Pourhabibi Zarandi N, Nzou G, Wicks R, Sadri-Ardekani H, Bishop C, Soker S, Hall A, Shupe T, Atala A. Skardal A, et al. Among authors: hall a. Biofabrication. 2020 Feb 26;12(2):025017. doi: 10.1088/1758-5090/ab6d36. Biofabrication. 2020. PMID: 32101533
These integrated systems proved to maintain viability and expressed functional biomarkers, long-term. Examples are provided that demonstrate how multi-organoid 'body-on-a-chip' systems may be used to model the interdependent metabolism and downstream effects of drugs acros …
These integrated systems proved to maintain viability and expressed functional biomarkers, long-term. Examples are provided that demo …
A Need For Long-Term Results of LMCA-CTO-PCI.
Cepas-Guillen P, Vásquez S, Fernandez-Valledor A, San Antonio R, Flores-Umanzor E, Martin-Yuste V, Xenogiannis I, Karmpaliotis D, Alaswad K, Basir MB, Yeh RW, Tamez H, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Khatri JJ, Sheikh AM, Malik BA, Greene ME, Abi Rafeh N, Maalouf A, Abou Jaoudeh F, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Gkargkoulas F, Russo J, Hakemi E, Tajti P, Hall AB, Vemmou E, Nikolakopoulos I, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Cepas-Guillen P, et al. Among authors: hall ab. J Invasive Cardiol. 2019 Nov;31(11):E342. J Invasive Cardiol. 2019. PMID: 31671069 Free article. No abstract available.
Patient education materials for non-specific low back pain and sciatica: A systematic review and meta-analysis.
Furlong B, Etchegary H, Aubrey-Bassler K, Swab M, Pike A, Hall A. Furlong B, et al. Among authors: hall a. PLoS One. 2022 Oct 12;17(10):e0274527. doi: 10.1371/journal.pone.0274527. eCollection 2022. PLoS One. 2022. PMID: 36223377 Free PMC article.
Compared to usual care for acute LBP, we found high to moderate-quality evidence that PEMs improved short-term pain intensity (SMD = -0.24 [95% CI: -0.42, -0.06]) and immediate-term quality of life (SMD = -0.24 [95% CI: -0.42, -0.07]). ...We found moderate to very l …
Compared to usual care for acute LBP, we found high to moderate-quality evidence that PEMs improved short-term pain intensity (SMD = …
Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study.
Wijeysundera DN, Pearse RM, Shulman MA, Abbott TEF, Torres E, Ambosta A, Croal BL, Granton JT, Thorpe KE, Grocott MPW, Farrington C, Myles PS, Cuthbertson BH; METS study investigators. Wijeysundera DN, et al. Lancet. 2018 Jun 30;391(10140):2631-2640. doi: 10.1016/S0140-6736(18)31131-0. Lancet. 2018. PMID: 30070222
FUNDING: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research, Innovation and Science, UK National Institute of Academic Anaesthesia, UK Clinical Research Collaboration, A …
FUNDING: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Ministry of Health and Long-Term Care …
Genetic Testing in Parkinson's Disease.
Pal G, Cook L, Schulze J, Verbrugge J, Alcalay RN, Merello M, Sue CM, Bardien S, Bonifati V, Chung SJ, Foroud T, Gatto E, Hall A, Hattori N, Lynch T, Marder K, Mascalzoni D, Novaković I, Thaler A, Raymond D, Salari M, Shalash A, Suchowersky O, Mencacci NE, Simuni T, Saunders-Pullman R, Klein C. Pal G, et al. Among authors: hall a. Mov Disord. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27. Mov Disord. 2023. PMID: 37365908 Free PMC article.
(2) How, if at all, should testing vary based on ethnicity? (3) What are the long-term outcomes of consumer- and research-based genetic testing in presymptomatic PD? ...
(2) How, if at all, should testing vary based on ethnicity? (3) What are the long-term outcomes of consumer- and research-based genet …
317 results